Behavioral and Biochemical Assays for Autism Models of Wistar Rats.
animal model
autism
behavior
biochemical changes
sodium valproate
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
30
10
2023
accepted:
10
01
2024
medline:
12
2
2024
pubmed:
12
2
2024
entrez:
12
2
2024
Statut:
epublish
Résumé
Being a "behavioral disorder," autism spectrum disorder (ASD) is difficult to manage because its precise etiology is uncertain. In order to better understand the pathophysiology of autism and explore various therapeutic approaches, animal models are developed. Animal models of autism caused by valproate during pregnancy exhibit strong construct validity and reliability. Hence, this study was done among autism-induced rats with the aim of identifying the behavioral and biochemical assays. Pregnant rats were administered sodium valproate on the 12th day of gestation, while control pregnant rats received normal saline. The rats' offspring that received normal saline during intrauterine life were grouped as control, and the rats' offspring that received valproate were grouped as autism-induced. From postnatal day (PND) 21, behavioral assessments were done by using the Y maze (repetitive behavior) and the T maze (social behavior). The estimation of antioxidant profile (malondialdehyde {MDA}, glutathione {GSH}, catalase (CAT), and superoxide dismutase {SOD}), proinflammatory markers (tumor necrosis factor {TNF} alpha, transforming growth factor {TGF} beta, interleukin {IL} 6, and IL-1 beta), neurotransmitters (gamma-aminobutyric acid {GABA} and serotonin), and brain-derived neurotrophic factor (BDNF) in the hippocampal region was done. Oxidative stress, increased proinflammatory markers, and increased serotonin were recorded in the autism group. Rats with autism had a significant decrease in GABA and BDNF levels. These biochemical alterations can be correlated with clinical features of autism to diagnose and manage the disorder at the earliest.
Identifiants
pubmed: 38344592
doi: 10.7759/cureus.52066
pmc: PMC10858314
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e52066Informations de copyright
Copyright © 2024, Ukkirapandian et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Neurochem. 2010 Sep 1;114(5):1414-23
pubmed: 20557420
Neural Plast. 2011;2011:297153
pubmed: 21766041
Front Psychiatry. 2021 Mar 12;12:549810
pubmed: 33776811
R Soc Open Sci. 2019 Jun 12;6(6):190574
pubmed: 31312505
Nat Rev Neurosci. 2002 Sep;3(9):715-27
pubmed: 12209120
Autism Res. 2009 Aug;2(4):205-19
pubmed: 19650112
Autism Res. 2017 Aug;10(8):1417-1423
pubmed: 28401654
Mol Cell Neurosci. 2014 Mar;59:57-62
pubmed: 24480134
Exp Neurol. 2018 Jan;299(Pt A):217-227
pubmed: 28472621
Front Psychiatry. 2011 May 13;2:27
pubmed: 21629840
Res Pract Thromb Haemost. 2019 Jul 16;3(4):566-577
pubmed: 31624776
Neurol Res. 2017 Jan;39(1):73-82
pubmed: 27809706
Biol Psychiatry. 2002 Oct 15;52(8):805-10
pubmed: 12372652
Trends Endocrinol Metab. 2017 Apr;28(4):297-308
pubmed: 28063767
Pathol Int. 2015 May;65(5):210-9
pubmed: 25707882
J Neurodev Disord. 2011 Jun;3(2):132-43
pubmed: 21484198
MMWR Surveill Summ. 2021 Dec 03;70(11):1-16
pubmed: 34855725
Neuroimmunomodulation. 2018;25(5-6):285-299
pubmed: 30157484
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jun 8;108:110185
pubmed: 33238165
Neuropsychopharmacology. 2008 Jan;33(1):73-83
pubmed: 17882234
Front Psychiatry. 2022 Mar 01;13:813304
pubmed: 35299821
Oxid Med Cell Longev. 2016;2016:3206561
pubmed: 27034733